Abstract
Nonalcoholic fatty liver disease (NAFLD) is considered to be a hepatic manifestation of metabolic syndrome. The clinicopathologic spectrum ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). Simple steatosis has a relatively benign clinical course, but NASH can progress to cirrhosis and hepatocellular carcinoma. As yet there is no convincingly effective treatment for NAFLD and the best option for these patients might be a multimodal treatment plan targeting obesity, insulin resistance, diabetes mellitus, hyperlipidemia and hypertension.
MeSH terms
-
Animals
-
Antioxidants / therapeutic use
-
Clinical Trials as Topic / statistics & numerical data
-
Combined Modality Therapy
-
Comorbidity
-
Contraindications
-
Diet, Diabetic
-
Diet, Reducing
-
Disease Progression
-
Ethanol
-
Fatty Liver / diet therapy
-
Fatty Liver / drug therapy
-
Fatty Liver / etiology
-
Fatty Liver / surgery
-
Fatty Liver / therapy*
-
Humans
-
Hypoglycemic Agents / therapeutic use
-
Hypolipidemic Agents / therapeutic use
-
Insulin Resistance
-
Life Style
-
Liver Transplantation
-
Metabolic Syndrome / complications
-
Metabolic Syndrome / diet therapy
-
Metabolic Syndrome / drug therapy
-
Mice
-
Mice, Obese
-
Mitochondria / drug effects
-
Mitochondria / metabolism
-
Phlebotomy
Substances
-
Antioxidants
-
Hypoglycemic Agents
-
Hypolipidemic Agents
-
Ethanol